Travere Therapeutics/$TVTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Ticker
- $TVTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 497
- Headquarters
- San Diego, United States
- Website
- travere.com
TVTX Metrics
BasicAdvanced
$5.9B
-
-$0.48
1.04
-
Price and volume
Market cap
$5.9B
Beta
1.04
52-week high
$68.73
52-week low
$22.06
Average daily volume
1.3M
Financial strength
Current ratio
4.046
Quick ratio
3.763
Long term debt to equity
24.906
Total debt to equity
25.157
Interest coverage (TTM)
-4.27%
Profitability
EBITDA (TTM)
22.913
Gross margin (TTM)
59.21%
Net profit margin (TTM)
-7.35%
Operating margin (TTM)
-6.84%
Effective tax rate (TTM)
-0.90%
Revenue per employee (TTM)
$1,190,000
Management effectiveness
Return on assets (TTM)
-3.73%
Return on equity (TTM)
-236.35%
Valuation
Price to revenue (TTM)
9.682
Price to book
241.02
Price to tangible book (TTM)
-55.24
Price to free cash flow (TTM)
377.558
Free cash flow yield (TTM)
0.26%
Free cash flow per share (TTM)
0.166
Growth
Revenue change (TTM)
77.12%
Earnings per share change (TTM)
-76.17%
3-year revenue growth (CAGR)
69.94%
10-year revenue growth (CAGR)
17.22%
3-year earnings per share growth (CAGR)
-52.74%
10-year earnings per share growth (CAGR)
-15.14%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Analyst projections of the future price of Travere Therapeutics stock.
Bulls say / Bears say
In April 2026, the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients with FSGS, making it the first and only FDA-approved therapy for this indication and expanding the U.S. addressable population by over 30,000 (SEC Filing).
U.S. net product sales of FILSPARI reached $141.1 million in Q2 2026 (96% YoY growth), driving first-half 2026 sales of $246.2 million (+93% YoY) and underscoring robust commercial momentum (SEC Filing).
In June 2026, partner Chugai Pharmaceutical submitted a New Drug Application for sparsentan in Japan, positioning Travere to earn milestone payments and tiered royalties from its international partnership (SEC Filing).
Enrollment in the pivotal Phase 3 HARMONY Study of pegtibatinase for HCU continues with topline data not expected until 2H 2027, creating a multi-quarter gap before potential approval-driven revenue (SEC Filing).
Despite revenue growth, Travere reported a GAAP net loss of $34.8 million in Q2 2026 (versus $12.8 million in Q2 2025), highlighting ongoing unprofitability amid heightened commercialization and R&D spending (SEC Filing).
Q2 2026 SG&A expenses surged to $96.1 million (up from $62.6 million YoY) and R&D expenses rose to $60.3 million (up from $49.4 million YoY), significantly increasing cash burn to support new product launches and pipeline development (SEC Filing).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TVTX News
AllArticlesVideos
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Business Wire3 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 week ago
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
MarketBeat1 month ago
Funds containing TVTX
AllUSDGBPEUR
Fund name | Fund size | $TVTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.40% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.40% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.19% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.